|
1
|
Rodier F and Campisi J: Four faces of
cellular senescence. J Cell Biol. 192:547–556. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
He S and Sharpless NE: Senescence in
health and disease. Cell. 169:1000–1011. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xue W, Zender L, Miething C, Dickins RA,
Hernando E, Krizhanovsky V, Cordon-Cardo C and Lowe SW: Senescence
and tumour clearance is triggered by p53 restoration in murine
liver carcinomas. Nature. 445:656–660. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brack C, Lithgow G, Osiewacz H and
Toussaint O: EMBO WORKSHOP REPORT: Molecular and cellular
gerontology Serpiano. Switzerland, September 18–22, 1999. EMBO J.
19:1929–1934. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Campisi J: Aging, cellular senescence, and
cancer. Annu Rev Physiol. 75:685–705. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Childs BG, Durik M, Baker DJ and van
Deursen JM: Cellular senescence in aging and age-related disease:
From mechanisms to therapy. Nat Med. 21:1424–1435. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Muñoz-Espín D and Serrano M: Cellular
senescence: From physiology to pathology. Nat Rev Mol Cell Biol.
15:482–496. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Alcorta DA, Xiong Y, Phelps D, Hannon G,
Beach D and Barrett JC: Involvement of the cyclin-dependent kinase
inhibitor p16 (INK4a) in replicative senescence of normal human
fibroblasts. Proc Natl Acad Sci USA. 93:13742–13747. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takahashi A, Ohtani N, Yamakoshi K, Iida
S, Tahara H, Nakayama K, Nakayama KI, Ide T, Saya H and Hara E:
Mitogenic signalling and the p16INK4a-Rb pathway cooperate to
enforce irreversible cellular senescence. Nat Cell Biol.
8:1291–1297. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Beauséjour CM, Krtolica A, Galimi F,
Narita M, Lowe SW, Yaswen P and Campisi J: Reversal of human
cellular senescence: Roles of the p53 and p16 pathways. EMBO J.
22:4212–4222. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Satyanarayana A and Kaldis P: Mammalian
cell-cycle regulation: Several Cdks, numerous cyclins and diverse
compensatory mechanisms. Oncogene. 28:2925–2939. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gire V and Dulic V: Senescence from G2
arrest, revisited. Cell Cycle. 14:297–304. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Burkhart DL and Sage J: Cellular
mechanisms of tumour suppression by the retinoblastoma gene. Nat
Rev Cancer. 8:671–682. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Arif A: Extraneuronal activities and
regulatory mechanisms of the atypical cyclin-dependent kinase Cdk5.
Biochem Pharmacol. 84:985–993. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Contreras-Vallejos E, Utreras E and
Gonzalez-Billault C: Going out of the brain: Non-nervous system
physiological and pathological functions of Cdk5. Cell Signal.
24:44–52. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Konecny GE: Cyclin-dependent kinase
pathways as targets for women's cancer treatment. Curr Opin Obstet
Gynecol. 28:42–48. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hall M and Peters G: Genetic alterations
of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human
cancer. Adv Cancer Res. 68:67–108. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen XX, Xie FF, Zhu XJ, Lin F, Pan SS,
Gong LH, Qiu JG, Zhang WJ, Jiang QW, Mei XL, et al:
Cyclin-dependent kinase inhibitor dinaciclib potently synergizes
with cisplatin in preclinical models of ovarian cancer. Oncotarget.
6:14926–14939. 2015.PubMed/NCBI
|
|
19
|
Martin MP, Olesen SH, Georg GI and
Schönbrunn E: Cyclin-dependent kinase inhibitor dinaciclib
interacts with the acetyl-lysine recognition site of bromodomains.
ACS Chem Biol. 8:2360–2365. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kumar SK, LaPlant B, Chng WJ, Zonder J,
Callander N, Fonseca R, Fruth B, Roy V, Erlichman C and Stewart AK:
Mayo Phase 2 Consortium: Dinaciclib, a novel CDK inhibitor,
demonstrates encouraging single-agent activity in patients with
relapsed multiple myeloma. Blood. 125:443–448. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Feldmann G, Mishra A, Bisht S, Karikari C,
Garrido-Laguna I, Rasheed Z, Ottenhof NA, Dadon T, Alvarez H,
Fendrich V, et al: Cyclin-dependent kinase inhibitor Dinaciclib
(SCH727965) inhibits pancreatic cancer growth and progression in
murine xenograft models. Cancer Biol Ther. 12:598–609. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Parry D1, Guzi T, Shanahan F, Davis N,
Prabhavalkar D, Wiswell D, Seghezzi W, Paruch K, Dwyer MP, Doll R,
et al: Dinaciclib (SCH 727965), a novel and potent cyclin-dependent
kinase inhibitor. Mol Cancer Ther. 9:2344–2353. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fu W, Ma L, Chu B, Wang X, Bui MM, Gemmer
J, Altiok S and Pledger WJ: The cyclin-dependent kinase inhibitor
SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma
cells. Mol Cancer Ther. 10:1018–1027. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stracker TH and Petrini JH: The MRE11
complex: Starting from the ends. Nat Rev Mol Cell Biol. 12:90–103.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kumar SK, Rajkumar V, Kyle RA, van Duin M,
Sonneveld P, Mateos MV, Gay F and Anderson KC: Multiple myeloma.
Nat Rev Dis Primers. 3:170462017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dhavan R and Tsai LH: A decade of CDK5.
Nat Rev Mol Cell Biol. 2:749–759. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ajay AK, Upadhyay AK, Singh S, Vijayakumar
MV, Kumari R, Pandey V, Boppana R and Bhat MK: Cdk5 phosphorylates
non-genotoxically overexpressed p53 following inhibition of PP2A to
induce cell cycle arrest/apoptosis and inhibits tumor progression.
Mol Cancer. 9:2042010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ogara MF, Belluscio LM, de la Fuente V,
Berardino BG, Sonzogni SV, Byk L, Marazita M and Cánepa ET:
CDK5-mediated phosphorylation of p19INK4d avoids DNA damage-induced
neurodegeneration in mouse hippocampus and prevents loss of
cognitive functions. Biochim Biophys Acta. 1843:1309–1324. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tian B, Yang Q and Mao Z: Phosphorylation
of ATM by Cdk5 mediates DNA damage signalling and regulates
neuronal death. Nat Cell Biol. 11:211–218. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huang E, Qu D, Zhang Y, Venderova K, Haque
ME, Rousseaux MW, Slack RS, Woulfe JM and Park DS: The role of
Cdk5-mediated apurinic/apyrimidinic endonuclease 1 phosphorylation
in neuronal death. Nat Cell Biol. 12:563–571. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Qu D, Rashidian J, Mount MP, Aleyasin H,
Parsanejad M, Lira A, Haque E, Zhang Y, Callaghan S, Daigle M, et
al: Role of Cdk5-mediated phosphorylation of Prx2 in MPTP toxicity
and Parkinson's disease. Neuron. 55:37–52. 2007. View Article : Google Scholar : PubMed/NCBI
|
